Cardiovascular · Clinical trials
Hypertrophic Cardiomyopathy Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About hypertrophic cardiomyopathy — and why its trials are hard
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder, caused predominantly by sarcomere protein gene mutations that produce inappropriate left-ventricular hypertrophy not explained by loading conditions. About two-thirds of patients have dynamic left-ventricular outflow tract (LVOT) obstruction, which drives exertional dyspnea, chest pain, presyncope, and syncope; HCM is also a leading cause of sudden cardiac death in the young. Traditional pharmacotherapy has been symptom-directed and negatively inotropic or lusitropic: beta-blockers, non-dihydropyridine calcium-channel blockers (verapamil, diltiazem), and disopyramide reduce obstruction and symptoms but do not target the underlying hypercontractile biology. Implantable defibrillators prevent sudden death in high-risk patients, and septal reduction therapy (surgical myectomy or alcohol septal ablation) relieves severe obstruction refractory to drugs. The transformative advance is the cardiac myosin inhibitor class, which directly reduces actin-myosin cross-bridge formation to lower contractility and outflow gradients. Mavacamten (first-in-class) and aficamten improve exercise capacity, symptoms, and gradients in obstructive HCM. These agents require echocardiographic monitoring of ejection fraction because of the risk of reversible systolic dysfunction.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Mavacamten (Camzyos) | 2022 | Symptomatic NYHA class II-III obstructive HCM (first cardiac myosin inhibitor) | EXPLORER-HCM (Lancet 2020) | Composite: >=1.5 mL/kg/min increase in pVO2 plus >=1 NYHA class improvement, OR >=3.0 mL/kg/min pVO2 increase with no NYHA worsening, at 30 weeks | Primary endpoint met by 37% on mavacamten vs 17% on placebo (difference 19 percentage points, p=0.0005); large reductions in LVOT gradients and improved health status |
| Aficamten (Myqorzo) | 2025 | Adults with symptomatic obstructive HCM to improve functional capacity and symptoms (next-generation cardiac myosin inhibitor) | SEQUOIA-HCM (NEJM 2024) | Change in peak oxygen uptake (pVO2) at 24 weeks | Least-squares mean difference +1.8 mL/kg/min favoring aficamten (p<0.001), with significant improvements across all 10 secondary endpoints including gradients, NYHA class, and KCCQ score |
| Disopyramide (Norpace) | Long-established (used off historic approval as class IA antiarrhythmic; guideline-recommended in HCM) | Obstructive HCM symptoms refractory to beta-blockers/verapamil (negative inotrope) | Observational/registry data (no modern pivotal RCT) | LVOT gradient reduction and symptom relief | Reduces resting outflow gradient and symptoms in obstructive HCM; anticholinergic effects and QT prolongation limit use (magnitude from registries, not RCT) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in hypertrophic cardiomyopathy development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Losartan (angiotensin receptor blocker) — INHERIT (Lancet Diabetes Endocrinol / randomized trial, 2013) | Losartan did NOT reduce left-ventricular mass or improve fibrosis/function versus placebo in HCM | The hypothesis that renin-angiotensin blockade would attenuate hypertrophy did not translate into structural benefit, so ARBs are not disease-modifying in HCM |
| Valsartan (early/subclinical HCM) — VANISH (JAMA Cardiology 2021) | In early sarcomeric HCM valsartan produced only a modest composite change with no clear clinical remodeling benefit | Small, surrogate-driven effect insufficient to establish ARBs as disease-modifying therapy in genotype-positive HCM |
Choosing the right endpoint
Primary endpoints that matter in hypertrophic cardiomyopathy trials
- Peak oxygen uptake (pVO2) — Cardiopulmonary exercise testing measure; primary endpoint in SEQUOIA-HCM and a component of the EXPLORER-HCM composite
- LVOT gradient (rest and Valsalva/post-exercise) — Echo measure of dynamic obstruction; myosin inhibitors produce large reductions
- NYHA functional class — Symptom classification; improvement is a key clinical endpoint for myosin inhibitors
- KCCQ / patient-reported health status — Quality-of-life instrument used as secondary endpoint in HCM myosin-inhibitor trials
- LVEF / systolic function monitoring — Safety endpoint; myosin inhibitors can cause reversible reductions in ejection fraction requiring REMS echo monitoring
How iNGENū runs hypertrophic cardiomyopathy trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Hypertrophic Cardiomyopathy clinical trials — FAQs
What makes cardiac myosin inhibitors different from beta-blockers in HCM?
Do mavacamten and aficamten prevent sudden cardiac death?
Why do patients on myosin inhibitors need echocardiogram monitoring?
Ready to discuss your hypertrophic cardiomyopathy trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal